GlassScriptPhysician profile
James C Marroquin
NPI 1902014392
$8,260.03
in general payments reported to CMS, 2019-2025
45 companies · $2,536 in 2025
The $2,536 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $197 · 2021: $281 · 2022: $725 · 2023: $1,457 · 2024: $2,312 · 2025: $2,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,244 · Education: $59.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,244.24 |
| Education | $59.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $994.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $783.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $757.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $587.25 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $486.68 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $453.81 | 2023-2025 | |
| Abbott Laboratories | $413.87 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.22 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $365.43 | 2024-2025 | Gemtesa, Myfembree |
| Abbvie INC. | $357.39 | 2019-2025 | |
| Astellas Pharma US INC | $226.70 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $225.78 | 2021-2025 | |
| Pfizer INC. | $211.83 | 2020-2025 | |
| Shield Therapeutics INC | $189.73 | 2022-2025 | Accrufer |
| Gilead Sciences, INC. | $168.81 | 2019-2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $166.60 | 2024-2025 | Corevalve Evolut R, Intellis Adaptivestim |
| Exact Sciences Corporation | $142.06 | 2024-2025 | Cologuard Collection Kit |
| Bard Peripheral Vascular, INC. | $124.99 | 2021 | |
| Merck Sharp & Dohme LLC | $115.18 | 2020-2025 | Gardasil 9, Capvaxive, Belsomra |
| Kowa Pharmaceuticals America, INC. | $93.51 | 2019-2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $91.66 | 2024-2025 | Voquezna |
| Dexcom, INC. | $90.35 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $87.18 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $64.33 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $58.07 | 2023 | Quviviq |
| Corium, LLC | $57.68 | 2023-2025 | Azstarys, Adlarity |
| Amarin Pharma, INC. | $55.75 | 2019-2020 | |
| Cleerly, INC. | $55.21 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Bausch Health US, LLC | $48.81 | 2023-2024 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $45.59 | 2022-2024 | Trintellix |
| Radius Health, INC. | $34.51 | 2025 | Tymlos |
| Cala Health, INC. | $34.02 | 2025 | Cala Kiq |
| Supernus Pharmaceuticals, INC. | $30.78 | 2023 | Qelbree |
| Tms Neurohealth Centers INC. | $30.63 | 2025 | Tms Neurohealth Centers INC. |
| Itamar Medical INC | $29.72 | 2024 | Watchpatone |
| Alvogen INC | $25.51 | 2024 | Teriparatide |
| Teva Pharmaceuticals USA, INC. | $24.62 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.51 | 2025 | Jornay Pm |
| Alk-Abello, INC | $24.37 | 2024 | Ragwitek, Odactra, Grastek |
| Ironshore Pharmaceuticals INC. | $22.87 | 2024 | |
| Viiv Healthcare Company | $20.18 | 2024 | Apretude |
| Inspire Medical Systems, INC. | $19.22 | 2023 | Inspire |
| Daiichi Sankyo INC. | $18.17 | 2022 | |
| Esperion Therapeutics, INC. | $13.80 | 2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Marroquin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.